1,000-Page Clinical Trial Dossier — 12 Languages — 10-Day Delivery

A Fortune 500 pharmaceutical company had a hard EMA submission deadline for a Phase 3 oncology trial dossier requiring simultaneous filing across all EU member states. The dossier comprised 1,000+ pages across six document types — trial protocol, investigator brochure, informed consent forms, patient information leaflets, summary of product characteristics, and labeling — each requiring localization into the 12 most commonly used EU languages covering coverage for Germany, France, Spain, Italy, Poland, Netherlands, Portugal, Sweden, Denmark, Finland, Czech Republic, and Hungary.

The client's previous vendor had attempted a sequential translation workflow that projected 30-35 business days for complete delivery — well past the EMA filing window. A competing vendor had quoted 20 days but required doubling the budget with no quality guarantee. Internal legal and regulatory teams were concerned about terminology consistency across the dossier components, particularly between the investigator brochure (written for clinicians) and patient-facing materials (written for lay audiences), both of which must cite identical drug names, dosing instructions, and safety information.

The client also required full EMA QRD template compliance across every language — mandatory font sizes, specific section ordering, bilingual product name formatting, and prescribed regulatory text — with zero tolerance for formatting errors that would trigger EMA review deficiencies and delay filing further.

DTP Labs structured the engagement around three core decisions that enabled the aggressive timeline. First, we deployed twelve dedicated language teams working in parallel, each with a lead linguist, reviewer, and DTP operator assigned exclusively to this project for the full 10-day window. This eliminated the queuing delays inherent in vendors with thin capacity who juggle multiple projects. Second, we built a comprehensive translation memory seeded from the client's prior EMA submissions, providing 60-70% leverage on standard clinical trial phrasing, regulatory text, and drug product information — which accelerated throughput without compromising quality.

Third, we used our CET 6am-6pm operations with weekend availability to provide near-continuous production coverage for the critical middle days of the project. Project management ran twice-daily standups with all 12 language leads plus client liaison, with real-time escalation paths for terminology decisions. A shared terminology database was updated continuously during the project, with approved translations propagating immediately to all 12 language teams to prevent inconsistencies between concurrent work streams.

For DTP production, operators worked directly in the client's Adobe InDesign source files, with master pages and paragraph styles preserved identically across all languages. QRD template compliance was verified against checklist-based QC with specific pass criteria for every EMA requirement. Every page underwent three-stage review: linguistic review by native speakers, regulatory QA against QRD template, and final client review via a shared review portal allowing the client's regulatory team to approve pages in parallel with production rather than waiting for complete language delivery.

All 12 language versions delivered on day 10, meeting the EMA filing deadline with three business days of buffer. The client submitted the complete dossier and received EMA validation with zero deficiencies cited against any of the localized documents — a critical outcome given that validation rejections typically add 30-60 days of rework and delay patient access to the therapy. Post-submission review by the client's external regulatory consultants confirmed that the localized documents met or exceeded the quality baseline set by the English source, with particular praise for terminology consistency across dossier components.

The engagement produced quantifiable commercial value for the client beyond the immediate submission. The therapy received regulatory approval three months ahead of internal planning targets, accelerating market launch. The translation memory and terminology database built during the project became foundational assets for subsequent submissions, with the client estimating 30-40% cost and time savings on all follow-on localization work. Most importantly, the engagement became the client's template for centralized procedure filings, with DTP Labs engaged as primary localization vendor for all subsequent major submissions across multiple therapeutic areas.

From a vendor relationship perspective, the project demonstrated the capacity advantages of dedicated in-house teams versus freelancer-dependent competitors. The client's procurement team cited the engagement in internal case discussions about vendor qualification, specifically noting the importance of ISO 27001 certification, in-house team capacity, and CET operations for regulated submissions.